<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVEFetuin-A, a hepatic secretory protein that simultaneously inhibits <z:hpo ids='HP_0003207'>arterial calcification</z:hpo> and insulin action, is associated with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, but its association with <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e>) is uncertain </plain></SENT>
<SENT sid="1" pm="."><plain>Preliminary studies suggest that the association of fetuin-A with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> might differ among individuals with or without type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>.RESEARCH DESIGN AND METHODSProspective study of 3,810 community-living individuals older than 65 years (511 with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>) and free of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> in 1992 when fetuin-A levels were measured </plain></SENT>
<SENT sid="2" pm="."><plain>Participants were followed-up for incident <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> through June 2008.RESULTSMean age was 75 years and 61% were women; 1,456 participants had an incident <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> event (248 among individuals with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>) </plain></SENT>
<SENT sid="3" pm="."><plain>The association of fetuin-A with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> was modified by type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (P interaction = 0.02) </plain></SENT>
<SENT sid="4" pm="."><plain>Higher fetuin-A was associated with lower <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> risk among persons without type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> [hazard ratio per SD 0.1 g/L higher fetuin-A, 0.93 (95% CI, 0.88-0.99)], whereas a trend in the opposite direction was observed among individuals with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, although it was not statistically significant [1.07 (0.93-1.22)] </plain></SENT>
<SENT sid="5" pm="."><plain>Among individuals without type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, similar effect modification was observed by <z:hpo ids='HP_0001513'>obesity</z:hpo> and <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>Consistently, higher fetuin-A was associated with lower <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> risk only in the subgroups without <z:hpo ids='HP_0001513'>obesity</z:hpo> or with HOMA-IR below the median [0.91 (0.85-0.97) and 0.87 (0.79-0.95), respectively].CONCLUSIONSThe association of fetuin-A with risk of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> differs among elderly individuals with and without <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> or type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>